Insmed to Hold Investor Call on Phase 3 ASPEN Study Results for Brensocatib in Bronchiectasis
BRIDGEWATER, N.J., May 27, 2024 — Insmed Incorporated, a global biopharmaceutical company dedicated to improving the lives of patients with serious and rare diseases, has announced a conference call and webcast scheduled for tomorrow, Tuesday, May 28, 2024, at 8:00 am ET. The purpose of this call is to discuss the topline results from the ASPEN study. This study is a global, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the efficacy, safety, and tolerability of brensocatib in patients suffering from non-cystic fibrosis bronchiectasis. A press release highlighting the topline results will be issued at approximately 6:30 am ET, prior to the commencement of the conference call.
Details for Participation
Stakeholders and interested individuals can join the conference call by dialing (800) 715-9871 for U.S. participants or (646) 307-1963 for international participants, using the access code 1245105. For those preferring to listen online, the conference call will be webcast live on the company's website.
For those unable to attend the live call, a replay will be available approximately one hour after the call's conclusion and will remain accessible until June 27, 2024. To access the replay, dial (800) 770-2030 for U.S. participants or (609) 800-9909 for international participants, again using the access code 1245105. The webcast will also be archived for 90 days under the Investor Relations section on the Insmed website.
About Insmed
Insmed Incorporated is a pioneering biopharmaceutical company aimed at transforming the lives of individuals with severe and rare diseases. The company's first commercialized product is a groundbreaking therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Insmed is actively developing a strong pipeline of investigational therapies targeting critical unmet medical needs, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. The company is also investing in an early-stage research program leveraging a wide array of advanced technologies, such as artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing.
Insmed's headquarters are located in Bridgewater, New Jersey, with additional offices and research facilities spread across the United States, Europe, and Japan.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
